NW Bio to expand cross-border supply of brain cancer product DCVax-L
The approvals will enable DCVax-L to be produced in Germany and supplied across borders to the UK for the clinical trials. The latest approvals for cross-border supply of
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.